Medicare Claims | Total Spending | Drug | Drug Class | Average Cost / Patient | % Correct |
---|---|---|---|---|---|
28.3M | $439M | Omeprazole | Gastrointestinal | $62 / yr | 73%
|
61.1M | $836M | Atorvastatin | Cardiovascular | $56 / yr | 67%
|
24.2M | $182M | Metformin | Endocrine | $31 / yr | 53%
|
44.2M | $310M | Amlodipine | Cardiovascular | $30 / yr | 40%
|
23.4M | $140M | Furosemide | Cardiovascular | $25 / yr | 40%
|
38.4M | $728M | Levothyroxine | Endocrine | $91 / yr | 40%
|
26.2M | $587M | Metoprolol | Cardiovascular | $95 / yr | 40%
|
33.0M | $622M | Gabapentin | Neurology | $90 / yr | 33%
|
4.6M | $2.83B | Lantus Solostar | Endocrine | $2,685 / yr | 27%
|
17.1M | $12.58B | Eliquis | Cardiovascular | $4,024 / yr | 20%
|
36.1M | $260M | Lisinopril | Cardiovascular | $30 / yr | 20%
|
2.0M | $2.62B | Ozempic | Endocrine | $5,717 / yr | 20%
|
6.4M | $5.23B | Xarelto | Cardiovascular | $4,154 / yr | 20%
|
29.4M | $393M | Losartan | Cardiovascular | $55 / yr | 13%
|
344K | $5.89B | Revlimid | Cancer | $129,242 / yr | 13%
|
3.7M | $4.70B | Trulicity | Endocrine | $7,084 / yr | 13%
|
375K | $2.91B | Humira Pen | Antirheumatic | $56,752 / yr | 7%
|
4.5M | $4.06B | Januvia | Endocrine | $4,344 / yr | 7%
|
3.8M | $3.74B | Jardiance | Cardiovascular | $4,224 / yr | 7%
|
231K | $3.15B | Imbruvica | Cancer | $120,958 / yr | 0%
|
Copyright H Brothers Inc, 2008–2024
Contact Us | Go To Top | View Mobile Site